0009

Jinling Pharmaceutical Co., Ltd. (000919)

Market Closed
16 May, 06:57
XSHE XSHE
¥
6. 65
+0.06
+0.91%
¥
4.15B Market Cap
- P/E Ratio
0.4% Div Yield
8,641,100 Volume
- Eps
¥ 6.59
Previous Close
Day Range
6.58 6.71
Year Range
5.55 7.85

Summary

000919 closed Friday higher at ¥6.65, an increase of 0.91% from Thursday's close, completing a monthly decrease of -0.3% or ¥0.02. Over the past 12 months, 000919 stock gained 0.61%.
000919 is not paying dividends to its shareholders.
The last earnings report, released on May 21, 2025, missed the consensus estimates by -0.05%. On average, the company has fell short of earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XSHE (CNY).
Want to track 000919 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

000919 Chart

Jinling Pharmaceutical Co., Ltd. (000919) FAQ

What is the stock price today?

The current price is ¥6.65.

On which exchange is it traded?

Jinling Pharmaceutical Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 000919.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 4.15B.

Has Jinling Pharmaceutical Co., Ltd. ever had a stock split?

No, there has never been a stock split.

Jinling Pharmaceutical Co., Ltd. Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Mr. Hai Chen CEO
XSHE Exchange
CNE0000010W5 ISIN
CN Country
5,789 Employees
- Last Dividend
10 Jul 2006 Last Split
27 Aug 1999 IPO Date

Overview

Jinling Pharmaceutical Company Limited is a distinguished entity in China's pharmaceutical sector, focusing on the manufacturing and distribution of a broad array of pharmaceutical products and medical devices. Founded in 1998 and rooted in Nanjing, China, the company has committed itself to addressing a range of health conditions through its extensive product offerings. It stands out for its dedication to innovation and quality in providing solutions for various medical needs, along with offering medical and health care services that further underscore its role in enhancing patient care and treatment outcomes.

Products and Services

Mailuoning Injection/Oral Solutions
Designed to treat an array of vascular diseases such as thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and its sequelae, polyarteritis, acute arterial embolism of the extremities, diabetic gangrene, intravenous thrombus, and thrombophlebitis, Mailuoning injection/oral solutions represent a pivotal part of Jinling Pharmaceutical’s product line.

Ferrous Succinate Tablets
These tablets are formulated to prevent and treat iron deficiency anemia, catering to patients who suffer from this condition by providing an essential mineral supplementation that contributes to the overall blood health and functionality.

Lentinan Injection
Aimed at the treatment of malignant tumors, lentinan injections embody Jinling Pharmaceutical's foray into oncology, offering a therapeutic solution that supports the standard cancer treatment protocols and potentially improves patient outcomes.

Absorbable Gelatin Sponges
This medical device is designed for wound hemostasis, suitable for various medical situations where rapid blood coagulation and healing are paramount. The sponges absorb bodily fluids and provide a scaffold for blood clotting, aiding in the wound healing process.

Contact Information

Address: Jinling Pharmaceutical Building, Nanjing, China, 210009
Phone: 86 25 8311 8511